Abstracts tagged "Pediatric rheumatology"

Abstract Number: 2043 • ACR Convergence 2023
Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease
Emily Dzongowski¹, Michael Miller¹, Melanie Schmidt¹, Nidhi Rashmikant Suthar¹, Thomas D Walters², Anne Griffiths², Wael El-Matary³, Eric Benchimol², Jennifer deBruyn⁴, Roberta A Berard¹ and Eileen Crowley¹, ¹Children's Hospital - London Health Sciences Centre, London, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Musculoskeletal (MSK) manifestations, including arthritis and arthralgia, are among the most common extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD), reported in 20-30% of…
Abstract Number: 2087 • ACR Convergence 2023
Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline
Bessie Roca Loor¹, Maya Pandit², Tracey Wright³ and Mill Etienne⁴, ¹New York Medical College, Yonkers, NY, ²Columbia University, New York, NY, ³UT Southwestern, Dallas, TX, ⁴New York Medical College, Valhalla, NY
Background/Purpose: The 2015 American College of Rheumatology Workforce study estimated the pediatric rheumatology full-time equivalent workforce to be 300 providers while the estimated excess demand…
Abstract Number: 0100 • ACR Convergence 2023
The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients
Jheel Pandya, Karen Onel and Doruk Erkan, Hospital for Special Surgery, New York, NY
Background/Purpose: The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti β2-glycoprotein-I (aβ2GPI) antibodies, is ill-defined in the pediatric…
Abstract Number: 0363 • ACR Convergence 2023
Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort
Michael Matt¹, Daniel Drozdov¹, Rolla Abu-Arja², Shanmuganathan Chandrakasan³, Kyla Driest², Elvira Cannizzaro Schneider⁴, Despina Moshous⁵, Benedicte Neven⁵, Karen Onel⁶, Sampath Prahalad⁷, Susan Prockop⁸, Pierre Quartier⁵, Johannes Roth⁹, Donna Wall¹⁰, Ulrike Zeilhofer¹¹, Scott Canna¹², Alexei Grom¹, Grant Schulert¹ and Rebecca Marsh¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Emory University School of Medicine, Atlanta, GA, ⁴Universitaetskinderspital Zurich, Zurich, Switzerland, ⁵Paris Cité Université and Necker Hospital, Paris, France, ⁶Hospital for Special Surgery, New York, NY, ⁷Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, ⁸Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children's Hospital of Zurich, Zurich, Switzerland, ¹²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Refractory systemic juvenile idiopathic arthritis (sJIA) in children can be complicated by repeated episodes of macrophage activation syndrome (MAS) or sJIA-related lung disease (sJIA-LD).…
Abstract Number: 0804 • ACR Convergence 2023
Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice
Leah M. Huey¹, Emily Vance¹, Holly L. Rosenzweig², Bryce Binstadt³ and Ruth J. Napier², ¹Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, VA Portland Health Care System, Portland, OR, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Microbial sensing molecule nucleotide-binding oligomerization-domain containing protein 2 (NOD2) is expressed by CD4+ T cells and plays a novel T cell-intrinsic role within CD4+…
Abstract Number: 1226 • ACR Convergence 2023
Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus
Ashley Danguecan¹, Ibrahim Mohamed², Sarah Mossad¹, Tala El Tal³, Adrienne Davis¹, Asha Jeyanathan¹, Sona Sandhu¹, Lawrence Ng¹, Paris Moaf¹, Deborah Levy¹, Linda Hiraki¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Brampton, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Problems with cognitive functioning are common in childhood-onset systemic lupus erythematosus (cSLE); these may be attributed to many factors including underlying brain inflammation. Socioenvironmental…
Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 1624 • ACR Convergence 2023
Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study
William Soulsby¹, Rebecca Olveda¹, Jie He², Laura Berbert², Edie Weller², Kamil Barbour³, Kurt Greenlund³, Laura Schanberg⁴, Emily von scheven¹, Aimee Hersh⁵, Mary Beth Son⁶, Joyce Chang² and Andrea Knight⁷, ¹University of California San Francisco, San Francisco, CA, ²Boston Children's Hospital, Boston, MA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Immunology, Boston Children's Hospital, Boston, MA, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Social determinants of health (SDoH) contribute to disparate outcomes in both adult and pediatric systemic lupus erythematosus (pSLE), including length of hospitalization, mortality, and…
Abstract Number: 2044 • ACR Convergence 2023
Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Alhanouf Alsaleem, Sulaiman Al-Mayouf and Shahad Alansari, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Background/Purpose: IFN-mediated diseases are mendelian innate immunodysregulatory disorders that present early in life with fevers, sterile organ inflammation, and a high type-I IFN-response gene signature…
Abstract Number: 2314 • ACR Convergence 2023
Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus
Emma Materne¹, Baijun Zhou¹, Hyon K. Choi², Yuqing Zhang³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Adolescent-onset SLE is associated with more severe disease than adult-onset SLE, but young adults may also experience adverse outcomes. We sought to compare disease…
Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Elizabeth Sloan¹, Katarina Kmetova², NaveenKumar K. Somanathapura², Lyndsay Kluge², Emily Chong², Claire Hoy², Srilakshmi Yalavarthi², Jacqueline Madison², Cyrus Sarosh², Lynnette Walters³, Jeanine Baisch⁴, Jessica Turnier², Virginia Pascual⁴, Tracey Wright¹, Jason Knight², Ayesha Zia¹ and Yu Zuo², ¹UT Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³Scottish Rite Hospital for Children, Dallas, TX, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
Abstract Number: 0364 • ACR Convergence 2023
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
Adam Mayer¹, Timothy G. Brandon², Pamela F. Weiss³ and on behalf of the JAXSPERT members², ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…
Abstract Number: 0830 • ACR Convergence 2023
The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis
Esraa Eloseily¹, Alex Pickering², Sanjeev Dhakal¹, Hermine Brunner³, Sherry Thornton⁴ and Alexei Grom¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Harvard Medical School Department of Biomedical Informatics, Boston, MA, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Despite significant progress in understanding the pathophysiology of Juvenile Idiopathic Arthritis (JIA), the availability of tools to accurately predict treatment response remains limited. Our…
Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Mersine Bryan¹, Jonathan Cogen¹ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
Abstract Number: 1244 • ACR Convergence 2023
Characterizing Lupus in African American Children in Southern United States
Anita Dhanrajani¹, Taylor Long², Spencer Hagwood², Cynthia Karlson² and Cali Foreman², ¹University of Mississippi Medical Center, New Orleans, LA, ²University of Mississippi Medical Center, Jackson, MS
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.